In-Vitro Anti-Cancer Studies Of Arctium Lappa L. Extract by Agha, Mohamad Taleb
IN-VITRO ANTI-CANCER STUDIES OF ARCTIUM 
LAPPA L. EXTRACT   
 
 
 
 
 
 
 
 
MOHAMAD TALEB AGHA 
 
 
 
 
 
 
 
 
 
UNIVERSITI SAINS MALAYSIA 
2017 
  
 IN-VITRO ANTI-CANCER STUDIES OF ARCTIUM 
LAPPA L. EXTRACT  
 
 
 
 
by 
 
 
 
 
MOHAMAD TALEB AGHA 
 
 
 
 
 
 
Thesis submitted in fulfillment of the requirements 
for the degree of 
Master of Science (Pharmacology) 
 
July 2017 
 
  
 
 
 
 
 
This thesis is dedicated to … 
My parents, 
My brother and sisters 
And People of Syria  
  
ii 
 
ACKNOWLEDGEMENT 
First and foremost, praise to Allah, the Most Gracious and the Most Merciful, for giving 
me the auspices and strength to finish this work.  
I would like to express my sincere gratitude to my supervisor Associate Professor Amin 
Malik Shah Bin Abdul Majid (School of Pharmaceutical Sciences, USM) for his 
constructive ideas, encouragement, constant guidance and patience throughout my study.  
My appreciations go to Mr. Hussein M. Baharetha for his extremely useful help and 
making things easier, and supporting me continuously during my study. I am also 
thankful for my other colleagues; Majid Al-mansoub, Yasser Tabana, Bassel Al-Hindi, 
Abdulmenem Bakkouri, Raghdaa Al-zarzour, Mohammed Asif, Muhammed Atta, and 
all academic and non-academic staff of USM for their support during my candidature. 
I would also like to thank Universiti Sains Malaysia for awarding me a postgraduate 
assistant scheme and access to facilities in the School of Pharmaceutical Sciences.  
Last but not least, I owe my greatest gratitude to my parents (Sameer and Wafaa), for 
their valuable and endless support, inspiration and prayers in supporting me to achieve 
success in my life. My uttermost appreciation to my brother and sisters (Alaa, Hala and 
Aula), brothers-in-law, uncles, nephews, nieces, cousins and friends for their prayers and 
encouragement. 
I also thank NatureCeuticals Sdn Bhd and Eman Biodiscoveries Sdn Bhd for funding 
this research work and providing access to their research facilities and instruments. 
 
iii 
 
TABLE OF CONTENTS 
ACKNOWLEDGEMENT ............................................................................................ ii 
TABLE OF CONTENTS ............................................................................................. iii 
LIST OF TABLES ........................................................................................................ ix 
LIST OF FIGURES ....................................................................................................... x 
LIST OF PLATES ..................................................................................................... xiii 
LIST OF ABBREVIATIONS ..................................................................................... xiv 
LIST OF UNITS ......................................................................................................... xix 
LIST OF SYMBOLS ................................................................................................... xx 
ABSTRAK..................................................................................................................xxi 
ABSTRACT..... .........................................................................................................xxiii 
CHAPTER ONE: INTRODUCTION.......................................................................... 1 
1.1 Cancer: ................................................................................................................. 1 
1.2 Cancer prevalence: ............................................................................................... 2 
1.3 Factors that have roles in cancer incidence: ......................................................... 3 
1.4 Classification of cancer types: ............................................................................. 5 
1.4.1 Tissue type: ................................................................................................. 5 
1.4.2 Targeted organs: ......................................................................................... 5 
1.5 Breast cancer: ....................................................................................................... 5 
1.5.1 Epidemiology of breast cancer: .................................................................. 6 
iv 
 
1.5.2 Types of breast cancer: ............................................................................... 6 
1.6 Angiogenesis: ....................................................................................................... 6 
1.7 Role of VEGF in the regulation of angiogenesis: ................................................ 7 
1.8 Role of hypoxia in angiogenesis pathway: ........................................................ 10 
1.9 Antiangiogenesis regulating factors: .................................................................. 12 
1.10 Cell death and apoptosis: ................................................................................. 13 
1.11 Signal transduction pathways in cancer: .......................................................... 17 
  1.11.1 Wnt /β-catenin signaling pathway: ....................................................... 18 
  1.11.2 Notch signaling pathway: ..................................................................... 19 
  1.11.3 p53 signaling pathway: ......................................................................... 20 
  1.11.4 TGF-β signaling pathway: .................................................................... 20 
  1.11.5 Cell cycle (pRB/ E2F) signaling pathway: ........................................... 21 
  1.11.6 NF-кB signaling pathway: .................................................................... 22 
  1.11.7 Myc/Max signaling pathway: ............................................................... 23 
  1.11.8 MAPK signaling pathways: .................................................................. 23 
1.12 Arctium lappa L. .............................................................................................. 24 
 1.12.1 Botanical source: ................................................................................... 24 
 1.12.2 Plant taxonomic classification: .............................................................. 27 
 1.12.3 Traditional uses: .................................................................................... 27 
 1.12.4 Pharmacological uses: ........................................................................... 28 
v 
 
 1.12.5 Phytochemical constituents: .................................................................. 32 
1.13 Aims and objectives: ........................................................................................ 35 
CHAPTER TWO: MATERIALS AND METHODS ............................................... 36 
2.1 Materials:............................................................................................................ 36 
2.2 Equipment and Apparatus: ................................................................................. 38 
2.3 Experimental animal: ......................................................................................... 40 
2.4 Plant collection and authentication: ................................................................... 40 
2.5 Extraction and fractionation: .............................................................................. 41 
2.5.1 Extraction by maceration: ........................................................................ 41 
2.5.2 Fractionation by separating funnel: .......................................................... 41 
2.5.3 Samples preparation: ................................................................................ 42 
2.6 Characterization and phytochemical study: ....................................................... 42 
2.6.1 Ultraviolet visible (UV-Vis) spectrophotometry: ..................................... 42 
2.6.2 Fourier Transform Infrared Spectrometry (FTIR): .................................. 43 
2.6.3 Gas Chromatography−Mass Spectrometry (GC-MS): ............................. 43 
2.6.4 Measurement of total phenolic content: ................................................... 44 
2.6.5 Determination of total flavonoids content: ............................................... 45 
2.6.6 DPPH free radical scavenging assay: ....................................................... 45 
2.7 Maintenance and culturing of cell lines: ............................................................ 46 
2.7.1 Cell lines and media: ................................................................................ 46 
vi 
 
2.7.2 Cell Culture and daily monitoring of cells: .............................................. 47 
2.7.3 Subculture of cell lines: ............................................................................ 48 
2.7.4 Cell counting: ........................................................................................... 49 
2.8 Cell viability assay (MTT assay): ...................................................................... 50 
2.8.1 Seeding of cells: ....................................................................................... 50 
2.8.2 Treatment of cells with extracts or fractions: ........................................... 50 
2.8.3 Measuring of cell viability with MTT: ..................................................... 51 
2.9 Ex Vivo antiangiogenic evaluation using rat aortic ring assay: .......................... 52 
2.9.1 Culture media: .......................................................................................... 53 
2.9.2 Preparation of rat aortic segments into culturing plates: .......................... 52 
2.9.3 Treatment of rat aortic segments in culturing plates: ............................... 54 
2.9.4 Image analysis for quantification of neovascularization: ......................... 54 
2.10 In Vitro apoptotic and anti-tumorigenic activity of EHX on MCF-7: ............. 55 
2.10.1 Signal pathways using Dual-Luciferase assay: ...................................... 55 
2.10.2 Nuclear chromatin condensation of MCF-7 cell line: ............................ 56 
2.10.3 Morphological changes in MCF-7 by  
           transmission electron microscope (TEM): ............................................. 56 
2.10.4 Colony formation assay on MCF-7 cell line: ......................................... 57 
2.10.5 Cell migration assay on MCF-7 cells: .................................................... 58 
2.10.6 Cell invasion assay of MCF-7 cells: ....................................................... 59 
vii 
 
2.11 In Vitro antiangiogenic potential:..................................................................... 61 
2.11.1 Colony formation assay of EA.hy926: ................................................... 61 
2.11.2 Endothelial cell migration assay:............................................................ 62 
2.11.3 Endothelial cell tube formation assay: ................................................... 62 
2.11.4 Measuring VEGF expression: ................................................................ 63 
CHAPTER THREE: RESULTS ................................................................................ 65 
3.1 Quantification of A. lappa crude extracts and ethanol’s fractions: .................... 65 
3.1.1 Amount of A. lappa crude extract: ........................................................... 65 
3.1.2 Amount of A. lappa fractions obtained from ethanol extract: .................. 66 
3.2 Characterization and phytochemical study of EHX fraction: ............................ 66 
3.2.1 UV-Vis spectrophotometry: ..................................................................... 66 
3.2.2 FTIR analysis of ETH extract and EHX fraction: .................................... 67 
3.2.3 GC-MS qualitative analysis: .................................................................... 68 
3.2.4 Total phenolic content of A. lappa ethanolic extract (ETH)  
         and its EHX: ............................................................................................. 71 
3.2.5 Total flavonoids content of A. lappa ethanolic extract (ETH)  
         and its EHX: ............................................................................................. 71 
3.2.6 Assay of DPPH scavenging activity: ........................................................ 71 
3.3 Cell viability studies: ......................................................................................... 72 
3.3.1 Screening of anticancer activity of the extracts on different cell lines: ... 72 
viii 
 
3.3.2 IC50 of the active extracts on MCF-7: ...................................................... 73 
3.3.3 Screening of anticancer activity of the fractions on MCF-7 and     
         EA.hy926: ................................................................................................. 75 
3.3.4 IC50 of the active fraction (EHX) on MCF-7 and EA.hy926: .................. 76 
3.4 Ex vivo Antiangiogenic investigation using rat aortic ring assay: ..................... 78 
3.4.1 Screening of antiangiogenic potential of A. lappa extracts: ..................... 78 
3.4.2 The IC50 value of the most active extract (ETH) on rat aorta rings: ........ 80 
3.4.3 Screening of antiangiogenic potential of A. lappa fractions: ................... 81 
3.4.4 The IC50 value of the most active fraction (EHX) on 
         rat aorta rings: ........................................................................................... 83 
3.5 In Vitro apoptotic and anti-tumorigenic activity of EHX fraction  
       on MCF-7: ......................................................................................................... 84 
3.5.1 Signal pathways using Dual-Luciferase assay: ........................................ 84 
3.5.2 Effect of EHX on nuclear morphology and chromatin condensation of  
         MCF-7 cells: ............................................................................................. 85 
3.5.3 Ultra-structural changes of MCF-7 by TEM: ........................................... 88 
3.5.4 Colony Formation Assay on MCF-7 Cell Line: ....................................... 90 
3.5.5 Cell migration assay on MCF-7: .............................................................. 92 
3.5.6 Inhibition of MCF-7 cells invasion by EHX: ........................................... 94 
3.6 In vitro anti-angiogenesis studies of EHX fraction: ........................................... 96 
ix 
 
3.6.1 Colony formation assay on EA.hy926 cell line: ....................................... 96 
3.6.2 Cell migration assay on EA.hy926: .......................................................... 98 
3.6.3 Effect of EHX fraction on endothelial tube formation: .......................... 100 
3.6.4 VEGF expression by MCF-7: ................................................................. 102 
CHAPTER FOUR: DISCUSSION .......................................................................... 103 
4.1 General discussion: .......................................................................................... 103 
4.2 Bioactivity tests of A. lappa: ............................................................................ 104 
4.2.1 Effect of extracts and fractions on cell viability by MTT assay: ........... 104 
4.2.2 Ex-vivo angiogenesis studies of A. Lappa extracts and fractions  
         on rat tissue segments: ............................................................................ 105 
4.3 Apoptotic effect of EHX: ................................................................................. 108 
4.4 Antiangiogenic activity of EHX: ..................................................................... 111 
CHAPTER FIVE: CONCLUSION ......................................................................... 114 
REFERENCES ......................................................................................................... 116 
APPENDICES  
 
 
 
 
x 
 
LIST OF TABLES 
Page 
Table  1.1 Some of oncogenes and tumor suppressor genes. 4 
Table ‎1.2 Comparison between Apoptosis and necrosis (Ronco et al., 2009). 16 
Table ‎1.3 Active ingredients of Arctium lappa L. 33 
Table ‎1.4 Nutrients content of Arctium lappa L. 34 
Table ‎3.1 Percentage of yield of A. lappa crude extracts. 65 
Table ‎3.2 Percentage of yield of A.lappa fractions. 66 
Table ‎3.3 IR absorption regions with the corresponding organic groups of ETH  
                 and EHX. 67 
Table ‎3.4 Interpretation of GC-MS and percentages of area of major isolated  
                 peaks of identified compounds found in the ethanolic extract (ETH) 
                 and the active n-hexane fraction (EHX). 69 
Table ‎3.5 Antioxidant activity of ETH extract and its fraction EHX. 71 
Table ‎3.6 Percentage of cell viability of the extracts. 73 
Table ‎3.7 Percentage of cells viability of the fractions. 75 
Table ‎3.8 Percentage of inhibition of micro-vessels outgrowth. 78 
Table ‎3.9 Percentage of inhibition of micro-vessels outgrowth. 81 
 
 
 
 
xi 
 
LIST OF FIGURES 
Page  
Figure ‎1.1 Morphological changes occurring during apoptosis (Kerr et al., 1972). 14 
Figure ‎2.1 Cell counting on hemocytometer. 49 
Figure ‎3.1 Concentration-activity curve of extracts (ETH: red-dotted curve and  
                  PT: blue-bold curve) on MCF7 cell line. 74 
Figure ‎3.2 Cell viability curve of (EHX) on MCF7( blue-dotted curve) and  
                  EA.hy926( red-bold curve). 77 
Figure ‎3.3 Micro-vessels outgrowth in rat ring aorta under microscope. 79 
Figure ‎3.4 Dose response curve of extract ETH on rat aorta ring neovascularization. 80 
Figure ‎3.5 Micrographic images of rat aorta ring assay illustrate the effect  
                  of A. lappa fractions (EHX, EEA, EB, and EW) on  
                  neovascularization at 100 µg/ml. 82 
Figure ‎3.6 Concentration-activity curve of fraction EHX using rat aorta ring assay. 83 
Figure ‎3.7 Effect of EHX on 10 signal pathways activity. 84 
Figure ‎3.8 Percentage of apoptotic indexes of breast cancer cell line (MCF-7) 
                  treated with 7.5, 15 and 30 μg/ml of EHX fraction. 86 
Figure ‎3.9 Morphological changes and chromatin condensation of MCF-7 cell line. 87 
Figure ‎3.10 Ultra-structural micrograph of MCF-7 cells by TEM. 89 
Figure ‎3.11 Shows the survival rate of MCF-7 cells after treatment with EHX. 91 
Figure ‎3.12 Percentage inhibiting migration of MCF-7 cells. 93 
Figure ‎3.13 Wounds closure (arrows) of treated MCF-7. 94 
Figure ‎3.14 Effect of EHX fraction on MCF7 cells invasion. 95 
Figure ‎3.15 Survival rate of EA.hy926 cells after treatment with EHX. 97 
Figure ‎3.16 Percentage of inhibition of EA.hy926 cells migration. 98 
Figure ‎3.17 Wounds closure (arrows) of treated EA.hy926. 99 
xii 
 
Figure ‎3.18 Shows the effect of tube formation assay by EA.hy926 after  
                    treatment  with EHX fraction. 101 
Figure ‎3.19 Percentage of inhibition of VEGF expression. 102 
 
  
xiii 
 
LIST OF PLATES  
Page  
Plate ‎1.1 Photos of A. lappa plant, root, and flower. ....................................................... 26 
  
xiv 
 
LIST OF ABBREVIATIONS 
ABC ATP-binding cassette 
A. lappa Arctium lappa L. 
Ang-1 Angiopoietins-1 
ANOVA Analysis of variance 
APC Adenomatous polyposis coli 
ATCC American Type Culture Collection 
ATP Adenosine triphosphate 
Bcl-1 and 2 B-cell lymphoma 1 and 2 
bFGF basic Fibroblast growth factor 
c-myc Myelocytomatosis oncogene cellular homolog 
CO2 Carbon dioxide 
Conc Concentration 
3D Three-dimensional 
DMEM Dulbecco's modified eagle medium 
DMSO Dimethyl sulphoxide 
DNA Deoxyribonucleic acid 
xv 
 
DPPH 1,1-Diphenyl-2-picrylhydrazyl 
e.g. For example 
ELISA Enzyme-Linked Immunosorbent Assay 
ER Estrogen receptor 
etc. Et cetera, it means “and other things” 
FTIR Fourier transform infrared spectrometry 
GA Gallic acid 
GAE Gallic acid equivalent  
GC-MS Gas chromatography mass spectrometry 
GTP Guanosine triphosphate 
HCT-116 Human colorectal carcinoma cell line 
HIFBS Heat-inactivated fetal bovine serum 
HIFs Hypoxia inducible factors 
i.e. That means 
IC50 Half-maximal inhibitory concentration 
IL Interleukin 
IFN Interferon 
xvi 
 
IR Infrared 
M199 Earle’s salt 
MCF-7 Human hormone sensitive and invasive breast cancer 
MDA-MB-231 Human hormone resistant breast cancer cell line 
MIF Migratory inhibitory factor 
MTT 3-(4,5-Dimethylthiazol-2-yl)-2,5diphenyl tetrazolium bromide 
mRNA Messenger Ribonucleic acid 
m/z Mass/charge ratio 
NO Nitric oxide 
OD Optical density 
ORP150 Oxygen-regulated protein 150 
p53 Tumor suppressor protein 53 
PBS Phosphate buffer saline 
PDGF Platelet-derived growth factor 
PE Plating efficiency 
PlGF Placenta growth factor 
PS Penicillin/streptomycin solution 
xvii 
 
RB Retinoblastoma protein 
ROS Reactive oxygen species 
RPMI-1640 Roswell Park Memorial Institute medium 
S. aureus Staphylococcus aureus 
SD Standard deviation 
SF Surviving fraction 
SPSS Statistical Package for the Social Sciences 
TEM Transmission electron microscopy 
Temp Temperature 
TGF-β Transforming growth factor- β 
TMX Tamoxifen 
TNF Tumor necrosis factor 
TSP-1 Thrombospondin-1 
USA United states of America 
USM Universiti Sains Malaysia 
UV Ultraviolet 
UV-Vis Ultraviolet visible 
xviii 
 
VEGF Vascular endothelial growth factor 
VEGFRs Vascular endothelial growth factor receptor  
vs. Versus 
v/v Volume/volume 
w/v Weight/volume 
w/w Weight/ weight 
 
  
xix 
 
LIST OF UNITS 
Cm Centimeter 
G Gram 
H Hour 
Kg Kilogram 
Mg Milligram 
Ml Milliliter 
Mm Millimeter   
mm
3 
Cubic millimeter 
Min Minute 
Pg Picogram 
U Unit 
Μg Microgram 
µl Micro litter 
Μ Micron 
 
  
xx 
 
LIST OF SYMBOLS 
Α Alpha 
Β Beta 
Ε Epsilon 
≈ Approximately equal to 
ºC Degree Celsius 
+ve Positive 
–ve Negative 
% Percent 
  
xxi 
 
KAJIAN ANTI KANSER IN VITRO UNTUK EKSTRAK ARCTIUM LAPPA L. 
ABSTRAK  
Kanser payudara adalah kanser kedua paling lazim dilaporkan dan penyebab 
kelima kematian di seluruh dunia. Kanser ini dikelaskan kepada dua jenis; reseptor-
estrogen (ER) negatif dan ER positif. Rawatan kanser payudara merangkumi 
pembedahan, kimia atau gabungan kedua-duanya. Arctium lappa L., sejenis rumpai yang 
boleh dimakan berasal dari Eropah Utara, dengan taburan sederhana di seluruh Asia dan 
Amerika, telah digunakan secara tradisional untuk merawat kanser, diabetes dan 
keradangan. Dalam kajian ini, asai MTT telah dijalankan untuk mengkaji potensi 
antikanser ekstrak dan fraksi A. lappa menggunakan jujukan sel kanser payudara 
hormon-sensitif (MCF-7), jujukan sel kanser kolorektal (HCT-116) dan jujukan sel 
normal (EA.hy926). MCF-7 didapati sangat sensitif terhadap ekstrak-ekstrak A. lappa, 
dengan ekstrak etanolik  menunjukkan kesan yang paling aktif. Fraksi n-heksana bagi 
ekstrak etanolik (EHX) menunjukkan aktiviti yang kuat terhadap kedua-dua jujukan sel 
MCF-7 dan EA.hy926 (IC50: 14.08 ± 3.64 and 27.25 ± 3.45 μg/ml, masing-masing). 
Perubahan morfologi di dalam jujukan sel MCF-7 yang dirawat telah dikaji 
menggunakan teknik mikroskop elektron transmisi. Kesan apoptosis yang jelas dikesan. 
Tambahan pula, EHX didapati menganggu proses metastatik sel kanser payudara 
melalui perencatan percambahan, migrasi, invasi dan kolonisasi sel. Kesan-kesan EHX 
terhadap 10 laluan isyarat kanser telah dikaji. Fraksi menaikkan regulasi p53, β TGF dan 
NFkB (p < 0.05) secara signifikan. Seterusnya, sifat-sifat antiangiogenik daripada EHX 
dinilai menggunakan model-model ex vivo dan in vitro. EHX telah menunjukkan kesan 
antiangiogenik yang mujarab kerana ia merencat sebahagian besar percambahan mikro 
xxii 
 
kapal tikus aorta (IC50 4.34 ± 1.64 μg / ml). Kajian in vitro selanjutnya menunjukkan 
EHX merencat migrasi dan kolonisasi sel-sel EA.hy926 dengan berkesan. Sebagai 
contoh, EHX pada kepekatan 14 µg/ml merencat pembezaan sel-sel endotelial dan 
pembentukkan salur baru sebanyak 93%. Ekspresi faktor pertumbuhan endotelial 
vaskular (VEGF) didapati berkurangan  sebanyak 54% di dalam sel-sel kanser yang 
dirawat dengan 30 µg/ml EHX. Analisis fitokimia EHX menunjukkan kandungan 
fenolik dan flavonoid yang lebih tinggi daripada ekstrak induk, dengan aktiviti 
antioksida yang besar. Lebih 20 kompaun telah dikenal pasti di dalam EHX, yang mana 
stigmasterol, beta-sitosterol, dan 3-O-acetyllupeol adalah kompaun utama. 
Kesimpulannya, kajian ini menunjukkan A. lappa mempunyai aktiviti antikanser dan 
antiangiogenik yang mungkin berguna di dalam rawatan kanser payudara. 
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IN-VITRO ANTI-CANCER STUDIES OF ARCTIUM LAPPA L. EXTRACT  
ABSTRACT  
Breast cancer is the second most common cancer and the fifth cause of death 
worldwide. It is classified into two types: estrogen-receptor (ER) negative and ER 
positive. Treatment of breast cancer could be surgical, chemical or a combination of 
both. Arctium lappa L., an edible weed indigenous to Northern Europe, with moderate 
representation across Asia and America, has been traditionally used to treat cancer, 
diabetes and inflammation. In this work, in vitro studies were conducted to investigate 
the anticancer potential of A. lappa extracts and fractions using a hormone-sensitive 
breast cancer cell line (MCF-7), a colorectal cancer cell line (HCT-116) and a normal 
cell line (EA.hy926). MCF-7 was found to be highly sensitive to A. lappa extracts, with 
the ethanolic extract being the most active. The n-hexane fraction of the ethanolic 
extract (EHX) showed strong activity against both MCF-7 and EA.hy926 cell lines 
(IC50: 14.08 ± 3.64 and 27.25 ± 3.45 μg/ml, respectively). Morphological alterations in 
treated MCF-7 were visualized using transmission electron microscopy techniques. 
Distinct apoptosis was detected. Furthermore, EHX was found to disrupt the metastatic 
cascade of breast cancer cells by inhibition of cell proliferation, migration, invasion and 
colonization. Effects of EHX on 10 major cancer pathways were also investigated. The 
fraction was found to significantly up-regulate p53, TGF β and NFkB (p < 0.05). 
Antiangiogenic properties of EHX were assessed using ex vivo and in vitro models. 
EHX was shown to be potently antiangiogenic as it substantially repressed the sprouting 
of micro-vessels in rat aorta (IC50 4.34 ± 1.64 µg/ml). Further in vitro studies showed 
EHX to strongly inhibit the migration and colonization of EA.hy926 cells. For At 14 
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µg/ml of EHX suppressed the differentiation of endothelial cells and the formation of 
neovascularization by 93%. The expression of the vascular endothelial growth factor 
(VEGF) was found to be down-regulated by 54% in cancer cells treated with 30 µg/ml 
of EHX. Phytochemical analysis of EHX showed higher phenolic and flavonoid contents 
than the parent extract, with a substantial antioxidant activity. Over 20 compounds were 
identified in EHX, of which stigmasterol, beta-sitosterol, and 3-O-acetyllupeol being the 
major active compounds. In conclusion, this work demonstrates that A. lappa has 
valuable anticancer activity and antiangiogenic properties that may be useful in breast 
cancer treatment.   
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CHAPTER ONE: INTRODUCTION 
1.1 Cancer: 
Cancer is a mass of tissue that occurs due to abnormal proliferation of cells which tend 
to metastasize to other distant body parts. Cancer is not one disease. It is a group of more 
than 100 different and distinctive diseases (Labuschagne et al., 2014). 
 
Normally, human cells grow and divide to form new cells as and when the body needs 
them. When cells grow old or become damaged, they die, and new cells take their place. 
When cancer develops, this regulatory process disrupts. As cells become more and more 
abnormal, old or damaged cells still survive when they should die, and new cells form 
when they are not needed. These extra cells tend to proliferate non-stop and form a mass 
of tissue called tumor (Hartwell and Kastan, 1994). 
 
Tumors are classified as cancerous tumors (malignant) or non-cancerous tumors 
(benign). Cancerous tumors means, the tumor cells are able to invade neighboring 
tissues and metastasize to other places in the body through the blood or the lymph 
system to form new tumors far from the primary. In contrast, benign tumors grow 
locally and do not spread out, and when surgically excised usually will not grow back, 
whereas malignant occasionally do (Khansur et al., 1987).  
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1.2 Cancer prevalence: 
Cancer still has been recording a high number of incidence and mortality around the 
world. So far, cancer is still leading the second causes of death after heart diseases 
(Siegel et al., 2015).  By 2012, we have witnessed 14.8 million new cases and 8.2 
million deaths caused by different sorts of cancer. Lung cancer was diagnosed as the 
most common with 1.82 million cases followed by breast cancer 1.67 million cases then 
1.36 million cases by colorectal cancer. The leading cause of cancer death were lung 
cancer (1.6 million deaths), followed by liver cancer (745,000 deaths), and stomach 
cancer (723,000 deaths) (Ferlay et al., 2015). 
 
Males are more susceptible to cancer and have a higher rate of mortality comparing to 
females. Among men, the widespread sites of cancer cases in 2012 were lung, prostate, 
colorectal, stomach, and liver cancer. While among women, the 5 widespread sites were 
breast, colorectal, lung, cervix, and stomach cancer (Jemal et al., 2011). 
 
In ASEAN region, the estimates were over 700,000 new cancer cases and 500,000 
cancer deaths in 2008. The most commonly diagnosed cancers were lung (98,143), 
breast (86,842) and liver cancers (74,777). The leading cause of death was lung cancer 
(85,772), liver cancer (69,115) and colorectal cancer (44,280) (Kimman et al., 2012).  
 
The National Cancer Institute in Malaysia reported that, 103,507 new incidence were 
diagnosed for the period 2007-2011. Whereas the most common cancer among 
Malaysian were breast at 17.7%, followed by colorectal 13.2%, and lung cancer 10.2% 
(National Cancer Institute, 2016).   
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Concluding, the rate of cancer mortality is higher in the less developed regions 
comparing to the developed due to lower quality of life and lack of health education 
(Ferlay et al., 2010). 
 
1.3 Factors that have roles in cancer incidence:  
Environmental carcinogens lead to abnormal proliferation of cells caused by gene 
mutation (Belpomme et al., 2007). The duration of exposure influences directly in 
increasing disease risk. Including, lifestyle, obesity, sun exposure, radiation, bacterial 
and viral pathogens (such as Helicobacter pylori, papilloma viruses, and hepatitis B or C 
virus) and chemical substances (such as tobacco, pesticides, asbestos, and industrial 
waste) (Wang and Chen, 2001). Some hormones are a key role in the development of 
cancers such as estrogen and testosterone in breast and prostate cancers (Cuzick, 2008).  
Age, sex, race, heredity, lifestyle, pregnancy, sexual activity, and physiological stress 
also play a considerable role in cancer incidences (Sneden, 2004). Genetics plays 
significant contribution towards cancer cases; classified as two classes of genes: proto-
oncogenes (stimulate growth of cancer cells) and tumor suppressor genes (stop the cell 
division mechanism and repress tumor growth), as shown in Table 1.1 (Weeraratna, 
2005, Sneden, 2004). 
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    Table ‎1.1 Some of oncogenes and tumor suppressor genes. 
Oncogenes Cancer Tumor suppressor genes       Cancer 
Abl Leukemia APC Stomach and colon 
Bcl-1 Breast P53 Many cancers 
c-myc Leukemia, lung, and breast VHL Kidney 
N-myc Neuroblastoma CDK4 Skin 
BCR-ABL Leukemia DPC4 Pancreas 
Ki-ras Lung, colon, ovarian BRCA1 Breast and ovarian 
N-ras Leukemia BRCA2 Breast 
CDKN2 Melanoma MSH2 and MSH6 Colon 
MDM2 Sarcoma MLH1 Colon 
PDGF Glioma RB Many cancers 
Erb-B Breast   
HPC1 Prostate   
RET Thyroid   
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1.4 Classification of cancer types:  
Cancer can be classified according to the following:  
1.4.1 Tissue type:  
There are three different types described as follow: carcinoma, sarcoma, and glioma. 
Carcinoma is widespread mostly where the tumor originates in the epithelial tissue. 
Sarcoma, when the tumor emerges in the connective tissue. Glioma is a tumor in non-
neuronal brain tissue (Yarbro et al., 2010). 
 
1.4.2 Targeted organs:  
Cancer can attack almost all organs in the body with different percentages of prevalence; 
starting from skin, blood (leukemia), brain, breast, lung, pancreatic, colon, kidney, 
prostate, ovarian and uterine (Sneden, 2004). 
 
1.5 Breast cancer:  
Breast cancer is probably the world’s first studied malignancy and it is a global priority. 
Research on the interplay between environment and genes has illuminated the workings 
of the disease and helped to identify who is really at risk (Woolston, 2015).   
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1.5.1 Epidemiology of breast cancer:  
Breast cancer is relatively 100 times more common in women than men (Kreiter et al., 
2014). It is the world’s second most prevalent cancer with 10.9% of all cancers, but it is 
the fifth cancer type that leads to death. Globally, 1.7 million women were diagnosed 
with breast cancer in 2012. This disease kills around 400,000 women annually 
(Woolston, 2015, Ferlay et al., 2010, Formenti et al., 2011).  
 
1.5.2 Types of breast cancer:  
Two types of breast cancer can be defined in accordance to age, estrogen receptor (ER) 
negative such as MDA-MB-231 which is most common diagnosed before menopause 
with a serious and high rate of mortality. The ER positive such as MCF-7 is diagnosed 
after menopause and characterized by a lower mortality rate (Formenti et al., 2011). The 
estrogen-dependent breast cancer (ER positive) increases the aggressiveness of 
malignant tumor in this type of breast cancer which is dependent on hormonal effect. In 
contrast, activation of estrogen receptor of ER negative breast cancer reduces the 
seriousness (Sheikh et al., 1993). 
 
1.6 Angiogenesis:  
Since the 70s, much work have been carried out to find better cancer treatment and one 
of the  many approaches includes the interception of tumor vasculature by disrupting its 
developmental stage, a process commonly identified as angiogenesis. Angiogenesis is a 
complicated process that plays considerable role physiologically in normal development 
of blood capillary, wound healing processes, embryonic development and for menstrual 
cycle including endothelial cell migration, colonization, proliferation and tube formation 
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(Lu et al., 2016, Folkman, 1971). But it is well established that unregulated angiogenesis 
participates in initiation and progression of many pathological states, such as obesity, 
cancer, inflammation, psoriasis and diabetic retinopathy. Malignant tumors generally 
tend to grow up larger than 1mm
3
 and that requires more oxygen and nutrients 
consuming. Hence building a new blood vessels network is crucial to support tumor 
growth by supplying their nutritional requirements. Without this network of capillary, 
tumors will not be able to survive and the metastasis of cancer cells to other localities 
will be definitely disrupted (Li et al., 2016, Eskens, 2004). Recently a number of 
antiangiogenic drugs have been approved for cancer therapy. These drugs are rated as 
adjuvants to standard chemotherapy regiments. One fine example is  in the treatment of 
lung cancer where the combinational use of the chemotherapeutic agents carboplatin and 
paclitaxel with bevacizumab (antiangiogenic agent), which was shown to boost 
treatment efficacy. Other new developed antiangiogenic agents include cediranib, 
axitinib, aflibercept, nintedanib, pazopanib, vatalanib, brivanib, sorafenib, sunitinib, and 
ramucirumab (Shankar et al., 2016, Aggarwal et al., 2012, Medinger and Mross, 2010). 
 
1.7 Role of VEGF in the regulation of angiogenesis:   
VEGF vascular endothelial growth factor was discovered more than a decade ago and 
described as a major hypoxia-inducible growth factor (Li and Eriksson, 2001). VEGFs 
are pivotal factors for regulation of blood, lymphatic, and nervous systems throughout 
the pregnancy (embryonic development) and wound healing. In adults, VEGFs still play 
a role to retain homeostasis of vessels. Also, VEGFs mediate neovascularization 
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including several pathological impairments and diseases such as cancer (Ahmed and 
Bicknell, 2009).  
 
VEGF is often referred to as VEGFA and is a member of bigger VEGFs family of 
growth factors. VEGFs family contains seven members, including VEGF-A, VEGF-B, 
VEGF-C, VEGF-D VEGF-E, VEGF-F, and PLGF (placental growth factor). In addition, 
there are specific tyrosine kinase receptors (VEGFRs), including VEGFR-1, VEGFR-2 
and VEGFR-3. These VEGFs differ in their expression pattern, receptor specificity and 
biological functions. VEGFA has been studied extensively comparing to other members 
of this family. VEGFA is a homodimer and it has eight distinguished variants 
(VEGF121, VEGF145, VEGF148, VEGF165, VEGF183, VEGF189, VEGF 110 and 
VEGF206) (Goel and Mercurio, 2013). It regulates blood vessel development and 
angiogenesis by binding to VEGFR-1 and VEGFR-2 receptors. VEGF-C and VEGF-D 
are activated by binding to VEGFR2 and VEGFR3 to control vascularization process 
during development and the lymphatic system in adults. VEGF-E is a specific factor in 
viruses and binds only to VEGFR-2 (Ahmed and Bicknell, 2009, Fong et al., 1995, 
Ferrara, 2001). 
 
In cancer, it has become evident that the role of VEGF is not limited to angiogenesis and 
vascular permeability (Senger, 2010). VEGF, for example, has influence on the immune 
cells that are present in the tumor microenvironment and, consequently, it  can 
affect the host response to tumors (Hansen et al., 2012). Moreover, VEGF 
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receptors may control the function of fibroblasts in the tumor stroma (Yaqoob et al., 
2012). VEGF releasing is activated by hypoxic factor (HIF-1α) in hypoxic region. 
Whereas, VEGF transcription is stimulated by some oncogenes that activate HIF-1 
expression; this increase tumor angiogenesis cascades (Ahmed and Bicknell, 2009). 
 
Angiogenesis cascade is resembled as endothelial cells colonization, proliferation, 
migration, differentiation and survival activities and regulated by binding of VEGF to 
VEGFR-2 through VEGF receptor tyrosine kinase (RTKs) signaling pathway. The 
phosphorylation of tyrosine residue will be induced by VEGFs, to control the signals of 
VEGFR-2, whereas four autophosphorylation sites are identified by VEGFs (tyrosine’s 
951, 996, 1054 and 1059) (Ahmed and Bicknell, 2009, Dougher and Terman, 1999, 
Jussila and Alitalo, 2002). Later on, VEGF transphosphatidylation reaction will activate 
a mediatory enzyme phospholipase D, the function of this enzyme is to regulate 
angiogenesis phenotype, and this activation requires tyrosine phosphorylation and 
protein kinase C. It mediates many processes initiating angiogenesis pathways such as 
endothelial cell migration (Seymour et al., 1996).  
 
VEGF also influences nitric oxide (NO) synthase, stimulates production of nitric oxide 
by mediation of VEGFR, this regulates sprouting of new blood vessels and increases 
endothelial cell proliferation and migration (Feliers et al., 2015). 
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1.8 Role of hypoxia in angiogenesis pathway:  
Various epigenetic or environmental influences control neovascularization of malignant 
tumors and metastasis process like hypoxia, hypoglycemia, and acidosis. Hypoxia is a 
deprivation state of oxygen supply, in which there is an induction of tumor growth. HIFs 
hypoxia inducible factors are transcription factors activated when hypoxic region take 
place. Hypoxia-inducible factor 1 (HIF-1) is the most known among HIFs; its structure 
includes two DNA-binding proteins (heterodimer), HIF-1α and aryl hydrocarbon nuclear 
translocator (HIF-1β or ARNT) (Ahmed and Bicknell, 2009). In addition to HIF-1α, 
there are two more in HIFs family: HIF- 2α and HIF-3α. HIF-2α has less influence in 
normal adults and tumor angiogenesis in comparison to HIF-1α and HIF-3α, but it 
affects directly during pregnancy period (embryonic development) (Leek et al., 2002).  
 
Hypoxia is a major driver for genetic expression of vascular endothelial growth factor 
(VEGF) (Goel and Mercurio, 2013). Moreover, other extra-cellular pathways also have 
substantial impact regarding to hypoxia induced angiogenesis include the ephrin/Eph 
receptor, roundabouts/slits, notch/delta, netrins/UNCs, angiogenin, endothelins 1 and 2, 
adrenomedullin, neuropillins, plexins, semaphorins, and a variety of intracellular protein 
families (hedgehog and sprout) (Ahmed and Bicknell, 2009, Bicknell and Harris, 2004). 
Furthermore, hypoxia regulates several other angiogenic pathways such as connective 
tissue growth factor (CTGF), which is a strong angiogenic factor in human breast cancer 
cells (Shimo et al., 2001); inducible endoplasmic reticulum oxygen-regulated protein 
150 (ORP150), which is increased as VEGF chaperone (Ozawa et al., 2001); leptin gene 
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up-regulated by HIF-1 (Ambrosini et al., 2002). In addition, stromal cell-derived factor 1 
(CXCL12) is controlled by HIF-1α and boosts VEGF expression and up-regulates 
migratory inhibitory factor (MIF) (Goel and Mercurio, 2013, Bacher et al., 2003). 
Likewise, hypoxia up-regulates angiopoietins cell-specific molecules (Ang-1, -2, -3 and 
-4 family) which up-regulate angiogenesis by binding to Tie receptors (Makrilia et al., 
2009), the placenta growth factor (PlGF) expression (Green et al., 2001), and many other 
polypeptide angiogenic factors, such as pyruvate and lactate which are glycolysis 
metabolites (Murray and Wilson, 2001). 
 
Reactive oxygen species (ROS) also has a contribution in signaling pathways of many 
biological cellular functions such as angiogenesis and tumor growth (Xia et al., 2007). It 
has been established that the endogenous hydrogen peroxide (H2O2) enhances VEGF10. 
It can also induce the angiogenesis cascade steps such as endothelial cell proliferation 
and migration (Hassan et al., 2014), in addition to microtubules morphogenesis (Shono 
et al., 1996). Hypoxia produces ROS, this increases the rate of angiogenesis processes 
(such as tube formation), thus antioxidant agents plays crucial role in modulating the 
angiogenesis process as their scavenging activity can reduce  ROS which in turn 
influences angiogenesis (Lelkes et al., 1998). 
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1.9 Antiangiogenesis regulating factors:  
The angiogenesis process is modulated by the activity of proangiogenic and 
antiangiogenic factors. Pathologically, the abnormal vascularization, which is resembled 
by sprouting or inhibition of the new blood vessels growth, is governed by perturbing 
the balance taking place among these factors (Tonini et al., 2003). There are many 
antiangiogenic factors that affect vascularization such as angiostatin, vasostatin, 
thrombospondins (TSP) (trimeric 450 kDa glycoproteins), interleukins, endostatin, 
interferons, calreticulin, and metalloproteinases inhibitors which are secreted from the 
dormant tumors to ensure the stability of the tumor size; at the same time, they have a 
positive effect on endothelial cell apoptosis (Tonini et al., 2003, Folkman, 2002).  
 
Angiostatin consists of plasminogen fragments, it inhibits extracellular matrix of 
endothelial cells but on the other hand it opposes the plasminogen up-regulated effect of 
invasion and migration. The combination of endostatin and angiostatin will lead to 
strong synergistic antiangiogenic activity (Zhang et al., 2012). Vasostatin is an amino 
acid domain of calreticulin, it represses proliferation and angiogenesis of endothelial 
cells (Shu et al., 2014). TSP-1 and the pigment epithelium-derived factor are responsible 
in controling endothelial cell apoptosis and suppress VEGF expression. They inhibit the 
basic fibroblast growth factor (bFGF) expression to block angiogenesis 
(Karahuseyinoglu et al., 2013, Volpert et al., 2002).  
 
Endostatin consists of collagen fragments; it is produced in the walls of the blood 
vessels. Its function on endothelial cells is to increase apoptosis and down-regulates the 
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invasion and migration cascade, and this occurs through the inhibitory effect on protein 
and cyclin D1 mRNA and hyper phosphorylated expression of the retinoblastoma gene 
(Alahuhta et al., 2015). Interferons alpha and beta (IFN-α and IFN-β) inhibit VEGF 
expression and they mediate endothelial cell proliferation and suppression of 
angiogenesis of neuroendocrine tumors (Von Marschall et al., 2003).  
1.10 Cell death and apoptosis: 
Cell death is a key event in cell biology. Cell death occurs normally via two biological 
processes; either apoptosis or autophagy which are both forms of programmed cell 
death. However, cell death might happen also by necrosis which is non-physiological 
process. Necrosis is an abnormal process caused by external factors as a result of injury 
or infection. (Kerr et al., 1972, Elmore, 2007). Apoptosis, programmed cell death, 
identified initially through the morphological changes of dying cells exhibiting specific 
characteristic patterns which are active membrane blebbing, cytoplasmic shrinkage, 
chromatin condensation, and, typically, fragmentation into membrane enclosed vesicles 
known as apoptotic bodies (O’Driscoll et al., 2006). Apoptosis is firmly controlled by 
complex molecular signaling systems. It plays a key role throughout the cell cycle and 
development, and it has a direct impact on cell stages like cell ageing, tissue remodeling, 
and morphogenesis. In this process the cells activate apoptotic genes and kill themselves 
in a controlled way. Apoptosis causes cells shrinkage during this process to rapidly 
being digested, thus, there are no leakages of their contents (Raff, 1998). Figure 1.1 
demonstrates the morphological changes occurring during the apoptosis process. 
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Figure ‎1.1 Morphological changes occurring during apoptosis (Kerr et al., 1972).   
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Apoptosis is regulated through intrinsic and extrinsic biochemical pathways. They both 
lead to activate caspases as the final step (Hengartner, 2000). The intrinsic apoptotic 
pathway play a crucial role in down-regulation of anti-apoptotic proteins from the bcl-
2 family (e.g. bcl-xL), an increase in mitochondrial membrane permeability and an 
increased release of cytochrome c into the cytoplasm, which in turn activates caspase-
9 and caspase-3 resulting in apoptotic damage (Yon et al., 2005). The extrinsic pathway 
is initiated by the activation of death receptors that involves the formation of a death-
inducing signaling complex (DISC), which contains Fas, a member of the TNF-α 
superfamily. DISC formation results in the activation of caspase-8, which activates 
caspase-3 and executing the cell (Medema et al., 1997).  
 
Necrosis is a term that describes uncontrolled process in which death takes place after 
exposure to an acute injury. The cells start to swell and burst then they spill their content 
out over the surrounding tissue and that leads to inflammation (Kaku et al., 2016). Table 
1.2 illustrates the differences between some of the major features of apoptosis and 
necrosis. The unregulated rate of apoptosis in the body, either increasing or reducing can 
cause many ailments, for examples, hematologic diseases (e.g., lymphocytopenia and 
plastic anemia), apoptosis hyper-activation associated with neurodegenerative diseases 
(e.g., Alzheimer‘s syndromes and Parkinson’s), and disease characterized with tissue 
damage (e.g., myocardial infarction). In contrast, reducing apoptosis rate causes cell 
survival and it is related to autoimmunity diseases (e.g., Systemic lupus erythematosus) 
and immortal cancer cells (Chamond et al., 1999). The profound understanding to the 
link between apoptosis and cancer has been realized through studying the kinetics of 
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tumor growth. These studies have shown the link between cell death and tumor growth. 
Whereas, the treated tumor with cytotoxic agents showed a high rate of apoptosis 
occurrence (Kerr et al., 1972).  
 
 
 
 
 
          Table ‎1.2 Comparison between Apoptosis and necrosis (Ronco et al., 2009). 
Feature Apoptosis Necrosis 
Exfoliation of cells Early, as single cells Late, as sheet of cells 
Plasma membrane structure  Blebbing Lost 
Plasma membrane integrity  preserved Lost  
Cell-cell adhesion Lost early Preserved 
Cell matrix adhesion Lost early Lost late 
Cytosolic content  Preserved  Released  
Chromatin  Condensed  Preserved  
Nuclear fragmentation Characteristic  Absent  
Apoptotic bodies Characteristic  Absent  
Phagocytosis  Characteristic  Absent  
Cell volume  Decreased  Increased  
Inflammation response  Absent  Characteristic  
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1.11 Signal transduction pathways in cancer: 
Cell cycle machinery is regulated by a number of pathways and related proteins, and any 
disturbance in these regulatory will lead to malignancy (Ghobrial et al., 2005, Kaufmann 
and Hengartner, 2001). As a kind of adaptation, cancer cells pursue to change the 
surrounding microenvironment to assist their growth and proliferation.   These changes 
take place when the tumor is exposed to any internal or external stimuli and respond 
through increasing or decreasing expression of certain proteins to ensure tumor stability, 
proliferation, invasion, and metastasis (Hanahan and Weinberg, 2000). The signal 
transduction pathway, which is intracellular biochemical reactions, is mainly responsible 
for controlling the expression of these certain proteins (Lobbezoo et al., 2003). Each 
pathway depends on activation of extracellular receptor. Activation of the receptor is 
interpreted into biological response and activates transcriptional factors which then 
translocate into the nucleus and bind with the DNA in specific binding sites (promoters) 
and trigger the transcription of mRNAs which later translated to proteins (Eccleston and 
Dhand, 2006). 
 
Oncogenic gene mutations results in a constitutive activation of signal transduction 
elements, simulating a condition of permanent activation of the receptor, even in the 
absence of the relevant growth factor (Hanahan and Folkman, 1996). Wnt, Notch, TGF-
β, Myc/Max, Hypoxia, MAPK pathways were found to be hyper-activated in cancer 
cells (Clevers, 2004, Soucek et al., 2008). In contrast, mutations in suppressor genes 
cause deactivation of some pathways which may act as checkpoints of cells proliferation 
such as p53 (Lu et al., 2013).  In order to treat cancer, these pathways can be targeted 
mainly with signal transduction modulators (STMs) to suppress tumor growth. The 
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STMs can control the pathway activity at many levels such as blocking receptors on cell 
surface, extracellular signals and the transcription factor, deactivation of the binding 
sites between the transcription factors with the promoters or repress the effects of further 
downstream genes (Lobbezoo et al., 2003). Many studies are targeting STMs and 
investigations reached an advanced stage pre-clinically and in clinical trials. Nowadays, 
there are several approved STMs drugs which are commercially available in the market; 
Nilotinib, trastuzumab, ponatinib, and imatinib (Zhao et al., 2014). 
 
1.11.1 Wnt /β-catenin signaling pathway: 
Wnt signaling pathway plays a key role for development process in normal cells as well 
as cancer by controlling gene expression, cell adhesion, cell polarity and cell behavior 
(Cadigan and Nusse, 1997). Wnt signals work through three pathways: Wnt/JNK 
pathways, Wnt /β-catenin pathway (known as canonical Wnt pathway) and the non-
canonical Wnt/Ca+2 (Clevers and Nusse, 2012). 
 
Researchers have discovered mutations in many components of Wnt /β-catenin pathway 
associated with many types of human cancers such as: melanoma, breast, prostate, and 
colon cancers (Morin et al., 1997, Verras and Sun, 2006, Chien et al., 2009). In addition, 
in colon cancer patients, studies revealed that 80% have mutations in APC (tumor 
suppressor gene) which its function was referred to as a down-regulator of Wnt pathway 
(Clevers and Nusse, 2012). The Wnt /β-catenin pathway regulates the expression of 
many of important oncogenes such as: cyclin D1, matrix metalloproteinase, and c-Myc 
genes which are pivotal in carcinogenesis as well as angiogenesis (Dihlmann and von 
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Knebel Doeberitz, 2005). So, targeting Wnt pathway can repress the tumor proliferation 
with aim of downregulation of this pathway (King et al., 2012). 
 
1.11.2 Notch signaling pathway: 
Notch cell signaling pathway contributes in various cellular functions such as 
proliferation, cell fate specification, apoptosis, differentiation, migration, angiogenesis, 
and adhesion (Takebe et al., 2014). The signaling cascade starts with the ligation of the 
four isoforms of Notch extracellular receptors (Kojika and Griffin, 2001). A study on T-
cell lymphoblastic leukemia patients presented the relation of Notch pathway with 
cancer, where there was 10% of patients possessing a constitutive activation of Notch 1 
receptor (Callahan and Raafat, 2001). Furthermore, according to Yabuuchi et al. (2013), 
the activation of any Notch isoforms will be well correlated with tumor growth and 
aggressiveness properties. Hyper-activation of Notch pathway signaling has been 
noticed in many types of cancer, including breast, lung, melanoma, pancreas, renal, and 
colon cancers (Capaccione and Pine, 2013, Farnie and Clarke, 2007, Sun et al., 2009). 
 
Many researches showed a strong connection between Wnt and Notch pathways in colon 
cancer (Wynn et al., 2014). Thus, a combination of Wnt and Notch inhibitor may affect 
synergistically on colon cancer cells (van Es and Clevers, 2005). 
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1.11.3 p53 signaling pathway: 
In 1980, researchers discovered the relation of cancer with p53 gene mutations as 
existed widely in all cancer cases. More than 50% of cancer patients have suppressed 
p53 in tumors. The mutations in p53 gene lead to the activation of other oncogenic 
pathways, and causes tumors to become more aggressive and resistant to chemotherapy 
as well as radiation (Muller and Vousden, 2013). The main role of p53 is to induce 
apoptosis and cell cycle arrest and it has been referred to as ‘Guardian of the Genome’ 
due to its decisive effect. p53 protein encodes many type of genes which are involved in 
apoptosis, angiogenesis, and cell cycle. p53 controls cell death particularly through the 
two apoptotic pathways (intrinsic and extrinsic). p53 activates death receptor DR-5 and 
Fas genes which are related to the extrinsic pathway as well as Bak, Bax, and Bid 
proteins which are related to the mitochondrial pathway (Yamasaki, 2003). According to 
Lowe et al. (1993), the study was performed on p53 knockout-mice and, as a result, a 
slowdown in the apoptosis process clearly occurred in addition to drug resistance. 
 
1.11.4 TGF-β‎signaling pathway: 
TGF-β signaling pathway is identified as a double-edged sword, the tumor suppressor 
and oncogenic properties of this pathway have been described in many studies (Katsuno 
et al., 2013). As a tumor suppressor, one research have found that TGF-β defect- mice 
were more susceptive to tumor incidence comparing to normal mice (Tang et al., 1998). 
In one  study on transgenic mice where the TGF-β was hyper-activated, it was shown 
that these mice were more resistant for mammary tumor formation (Pierce et al., 1995). 
In another study on  in vitro cancer cells it was found that the cells tend to secret TGF-β 
proteins more than normal cells (Roberts et al., 1983). And clinically, TGF-β levels in 
